BDSI BioDelivery Sciences International Inc.

3.95
+0.16  (+4%)
Previous Close 3.79
Open 3.86
Price To Book 5.49
Market Cap 380,562,730
Shares 96,344,995
Volume 747,499
Short Ratio
Av. Daily Volume 1,174,437
Stock charts supplied by TradingView

NewsSee all news

  1. BioDelivery Sciences Reports Strong Fourth Quarter and Full-Year 2019 Results

    Full-Year Total Company Net Sales Increased 100% versus Prior Year to $111.4 Million Full-Year BELBUCA® Net Sales Increased 112% versus Prior Year to $97.5 Million Fourth Quarter Total Company Net Sales Increased 75%

  2. BioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of Directors

    RALEIGH, N.C., March 09, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  3. BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine's 36th Annual Meeting

    BELBUCA® Effect on Respiratory Drive was Comparable to Placebo in Clinical Trial at all Tested Doses Immediate Release Oral Oxycodone HCl Associated with a Dose-Dependent Decrease in Respiratory Drive Compared to

  4. BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    RALEIGH, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  5. BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic

    2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million More than 25 Million Additional Lives Moved to Preferred Coverage for Symproic® effective January 1, 2020 RALEIGH, N.C., Jan.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. BioDelivery Sciences Reports Strong Fourth Quarter and Full-Year 2019 Results

    Full-Year Total Company Net Sales Increased 100% versus Prior Year to $111.4 Million Full-Year BELBUCA® Net Sales Increased 112% versus Prior Year to $97.5 Million Fourth Quarter Total Company Net Sales Increased 75%

  2. BioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of Directors

    RALEIGH, N.C., March 09, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  3. BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine's 36th Annual Meeting

    BELBUCA® Effect on Respiratory Drive was Comparable to Placebo in Clinical Trial at all Tested Doses Immediate Release Oral Oxycodone HCl Associated with a Dose-Dependent Decrease in Respiratory Drive Compared to

  4. BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    RALEIGH, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  5. BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic

    2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million More than 25 Million Additional Lives Moved to Preferred Coverage for Symproic® effective January 1, 2020 RALEIGH, N.C., Jan.

  6. BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development

    RALEIGH, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  7. BioDelivery Sciences Added to NASDAQ Biotechnology Index

    RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  8. Emmy® and Tony Award® Winning Actress Kristin Chenoweth Introduces 'This Is Pain' Campaign to Improve the Lives of Those Living with Chronic Pain

    RALEIGH, N.C., Dec. 11, 2019 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  9. BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    RALEIGH, N.C., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  10. BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors

    RALEIGH, N.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  11. BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations

    BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million Raises Full Year 2019 Total Company Net Sales Expectations to $105 - $110 Million Provides Full Year 2020 BELBUCA Net Sales

  12. BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London

    RALEIGH, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  13. BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019

    RALEIGH, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its

  14. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

  15. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company

  16. BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

    Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.C.,

  17. BioDelivery Sciences Announces Participation in Upcoming Investor Conferences

    RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  18. BioDelivery Sciences Announces Upcoming Investor Conference Presentations

    RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  19. BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management

    RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today